A pivotal trial of PLX-R18 in acute radiation syndrome (ARS)
Phase of Trial: Phase III
Latest Information Update: 10 May 2018
At a glance
- Drugs PLX R18 (Primary)
- Indications Acute radiation syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Pluristem Therapeutics
- 10 May 2018 According to Pluristem Therapeutics media release, the company anticipates FDA clearance for this trial by the end of 2018.
- 07 Feb 2018 According to Pluristem Therapeutics media release, company is collaborating with the U.S. Department of Defense (DOD) Armed Forces Radiobiology Research Institute (AFRRI). This study is conducted and funded by AFRRI and data from this study is expected in 2018.
- 25 Oct 2017 New trial record